Ryan R. Willard - Concepedia

Concepedia

Author

Ryan R. Willard

Arvinas (United States)ORCID

Also Known As

R R. Willard, R Willard, R. Willard, Rebecca Willard, Robert J. Willard, Ryan R Willard, Ryan R. Willard, Ryan Willard

35

Publications

2.4K

Citations

13

H-Index

45

Concepts

All Affiliations

Arvinas (United States)Yale University University of New Haven Beltsville Agricultural Research Center Agricultural Research Service

RR

About

Ryan R. Willard is an author at Arvinas (United States) specializing in medicine, protein degradation, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	655
2	Health Sciences	7	7	590
3	Biochemistry	3	3	1.3K
4	Natural Sciences	2	2	1.3K
5	Biomedical Engineering	1	1	10

Ryan R. Willard

×

15

Publications

2.4K

Citations

13

H-Index

	Year	Citations
Catalytic in vivo protein knockdown by small-molecule PROTACs Daniel P. Bondeson, Alina Mares, Ian E. Smith, Nature Chemical Biology BiochemistryProtein AssemblyNatural SciencesVivo ProteinSmall Molecules	2015	1.3K
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance Jemilat Salami, Shanique Alabi, Ryan R. Willard, Communications Biology	2018	334
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer. Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard, Journal of Clinical Oncology Androgen ReceptorTumor BiologyMolecular PharmacologyOncologyGenitourinary Cancer	2019	199
Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer JJ Flanagan, Yimin Qian, SM Gough, Cancer Research Breast OncologyEstrogen ReceptorGynecologyCancer BiologyMammary Gland Development	2019	130
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh, Clinical Cancer Research	2024	120
Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer Lawrence B. Snyder, John J. Flanagan, Yimin Qian, Cancer Research Breast OncologyEstrogen ReceptorPharmacotherapyCancer BiologyMammary Gland Development	2021	105
Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer Lawrence B. Snyder, Taavi K. Neklesa, Xin Chen, Cancer Research Androgen ReceptorPharmacotherapyUbiquitin ProteomicsCancer BiologyTumor Biology	2021	69
Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard, Cancer Research Androgen ReceptorUrologyGenitourinary CancerMedicineAr Gene	2018	59
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader Lawrence B. Snyder, Taavi K. Neklesa, Ryan R. Willard, Molecular Cancer Therapeutics	2024	38
An oral androgen receptor PROTAC degrader for prostate cancer. Taavi K. Neklesa, Lawrence B. Snyder, Mark Bookbinder, Journal of Clinical Oncology Molecular PharmacologyMedicinal ChemistryUrologyAndrogen ReceptorAr Degradation	2017	27

Page 1